Ganoderma lucidum is an inhibitor of testosterone-induced prostatic hyperplasia in rats

Andrologia

Volumn 44, Issue SUPPL.1, 2012, Pages 160-174

  Nahata, A ^a   Dixit, Vinod K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

5 reductase; Benign prostatic hyperplasia; Ganoderma lucidum; Prostate specific antigen; Testosterone

Indexed keywords

ARACHIS OIL; FINASTERIDE; GANODERMA LUCIDUM EXTRACT; PROSTATE SPECIFIC ANTIGEN; SITOSTEROL; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROSTATE HYPERTROPHY; RAT; URINE VOLUME;

ANIMALS; CHROMATOGRAPHY, THIN LAYER; FINASTERIDE; MALE; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; REISHI; TESTOSTERONE;

EID: 84861489337     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/j.1439-0272.2010.1155.x     Document Type: Article

References (42)

1. American Herbal Pharmacopoeia (2006) Reishi mushroom Ganoderma lucidum standards of analysis, quality control, and therapeutics. In: American Herbal Pharmacopoeia and Therapeutic Compendium. Anonymous. American Herbal Pharmacopoeia, Scotts Valley, CA, pp 10-12.
2. Bartsch G, Rittmaster RS, Klocker H (2000) Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. Eur Urol37:367-380.
3. Bartsch G, Rittmaster RS, Klocker H (2002) Dihydrotestosterone and the concept of 5α -reductase inhibition on human benign prostatic hyperplasia. World J Urol19:413-425.
4. Berges RR, Windeler J, Trampisch HJ, Senge T (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet345:1529-1532.
5. Bombardelli E, Morazzoni P, Small JK (1997) Serenoa repens (13artram). Fitoterapia68:99-113.
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem72:248-254.
7. Braeckman J (1994) The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res55:776-785.
8. Carbajal D, Arruzazabala ML, Mas R, Molina V, Rodriguez E, Gonzalez V (2004) Effects of D-004, a lipid extract from Cuban royal Palm fruit, on inhibiting Prostatic hypertrophy induced with testosterone or dihydrrotestosterone in a rat model: a randomized, controlled study. Curr Ther Res65:505-514.
9. Carson CI, Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology61:2-7.
10. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA274:1214-1220.
11. Deslypere JP, Young M, Wilson JD, McPhaul MJ (1992) Testosterone and 5 c∼-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol88:15-22.
12. Dhanotiya R, Chauhan NS, Saraf DK, Dixit VK (2009) Effect of Citrullus colocynthis Schard. on testosterone-induced Benign Prostatic hyperplasia. J Complement Integr Med6:art 29.
13. Fujita R, Liu J, Shimizu K, Konishi F, Noda K, Kumamoto S, Ueda C, Tajiri H, Kaneko S, Suimi Y, Kondo R (2005) Anti-androgenic activities of Ganoderma lucidum. J Ethnopharmacol102:107-112.
14. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens Ch, Kantoff PW (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci94:3320-3323.
15. Hsing AW, Reichardt JK, Stanczyk FZ (2002) Hormones and prostate cancer: current perspectives and future directions. Prostate52:213-235.
16. Iehle C, Radvanyi F, Medina S, Ouafik LH, Gerard H, Chopin D, Raynaud JP, Martin PM (1999) Differences in steroid 5α -reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol68:189-195.
17. Jenkins EP, Hsieh CL, Milatovitch A, Normington K, Berman DM, Francke U, Russell DW (1991) Characterization and chromosomal mapping of a human steroid 5α-reductase gene and pseudogene and mapping of the mouse homolog. Genomics11:1102-1112.
18. Jian JH, Slivova V, Valachovicova T, Harvey K, Sliva D (2004) Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostatae cancer cells PC-3. Int J Oncol24:1093-1099.
19. Klippel KF, Hiltl DM, Schipp B (1997) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol80:427-432.
20. Liu J, Shimizu K, Konishi F, Noda K, Kumamoto S, Kurashiki K, Kondo R (2007) Anti-androgenic activities of the triterpenoids fraction of Ganoderma lucidum. Food Chem100:1691-1696.
21. Mahapokai W, Van Sluijs FJ, Schalken JA (2000) Models for studying benign prostatic hyperplasia. Prostate Cancer Prostatic Dis3:28-33.
22. Martindale (1989) The Extra Pharmacopoeia, 29th edn. In: Reynolds JEF (ed.). The Pharmaceutical Press, London, pp 1203
23. Nandecha C, Nahata A, Dixit VK (2010) Effect of Benincasa hispida fruits on testosterone induced prostatic hypertrophy in albino rats. Curr Ther Res Clin Exp71: 331-343.
24. Nilsson O, Peter A, Andersson I, Nilsson K, Grundstrom B, Karlsson B (1997) Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA. Br J Cancer75:789-797.
25. Noguchi M, Kakuma T, Tomiyasu K, Yamada A, Itoh K, Konishi F, Kumamoto S, Shimizu K, Kondo R, Matsuoka K (2008) Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms. Asian J Androl10:777-785.
26. OECD 423 (2001) OECD Guideline For Testing of Chemicals Acute Oral Toxicity - Acute Toxic Class Method Adopted: 17th December 2001.
27. Pandit S, Chauhan NS, Dixit VK (2008) Effect of Cuscuta reflexa Roxb. on androgen-induced alopecia. J Cosmetic Dermatol7:199-204.
28. Paubert-Braquet M, Richardson FO, Servent-Saez N (1996) Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res34:171-179.
29. Purdon MP, Lehman-McKeeman LD (1997) Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites. J Pharmacol Toxicol Methods37:67-73.
30. Roll R, Höfer-Bosse T, Kayser D (1986) New perspectives in acute toxicity testing of chemicals. Toxicol Lett Suppl31:86.
31. Ross RK, Bernstein L, Pike MC, Henderson BE, Lobo RA, Stanczyk FZ, Pike M, Henderson B (1992) 5α-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet339:887-889.
32. Russell DW, Wilson JD (1994) Steroid 5α-reductase: two genes/two enzymes. Annu Rev Clin Biochem63:25-61.
33. Steers WD (2001) 5α-Reductase activity in the prostate. Urology58:17-24.
34. Tang W, Liu J, Zhao W, Wei D, Zhong J (2006) Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci80:205-211.
35. The Merck Index (2006). Encyclopedia of chemicals, drugs, and biologicals, 14th edn. O'Neil MJ, Heckelman PE, Koch CB, Roman KJ (eds). Merck Research Laboratories, Merck & Co., Whitehouse Station, NJ, USA, pp 1475.
36. Thompson IM, Phyllis J, Goodman PJ, Tangen CM, Scott Lucia M, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med349:215-224.
37. Uygur MC, Gur E, Ariki AI, Altug U, Erol D (1998) Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospective study. Andrologia30:5-10.
38. Wasser SP, Weis AL (1999) Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol19:65-96.
39. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA280:1604-1609.
40. Wilt TJ, Macdonald R, Ishani A (1999) β-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int83:976-983.
41. Yun TK (1999) Update from Asia. Asian studies on cancer chemoprevention. Ann NY Acad Sci889:157-192.
42. Zhou ZX, Lane MV, Kemppainen JA (1995) Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol9:208-218.